Novel Immunotherapy Combinations for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on systemic steroid therapy or any immunosuppressive medication, you must stop at least 3 days before the first dose of the study drug.
Is the novel immunotherapy combination for lung cancer safe for humans?
What makes the drug combination of Dostarlimab, GSK4428859A, and Pembrolizumab unique for lung cancer?
This drug combination is unique because it involves novel immunotherapy agents like Dostarlimab and Pembrolizumab, which are both PD-1 inhibitors (drugs that block a protein on immune cells to help them attack cancer cells), and GSK4428859A, which may offer a new approach to treating lung cancer by potentially enhancing the immune response against tumors.12346
What data supports the effectiveness of the drug combination including Dostarlimab and Pembrolizumab for lung cancer?
Who Is on the Research Team?
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) that hasn't been treated before and has high PD-L1 levels. Participants should be in good physical condition, not have had certain lung diseases or recent major surgeries, and must not be taking immunosuppressive drugs. Smokers need to have smoked more than 100 cigarettes in their lifetime.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive novel immunotherapy combinations or monotherapy for advanced/metastatic non-small-cell lung cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dostarlimab
- GSK4428859A
- Pembrolizumab
Dostarlimab is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
iTeos Therapeutics
Industry Sponsor